Minimally Invasive Glaucoma Surgery Devices Market - Global Forecast 2025-2030

Minimally Invasive Glaucoma Surgery (MIGS) devices are reshaping modern ophthalmology by meeting evolving clinical needs for safer, less invasive treatments. Driven by advancements in surgical technique, regulatory developments, and payer incentives, the MIGS market continues to attract investment and adoption from leading healthcare stakeholders.

Market Snapshot: Minimally Invasive Glaucoma Surgery Devices Market

The Minimally Invasive Glaucoma Surgery Devices Market grew from USD 585.26 million in 2024 to USD 618.15 million in 2025. It is projected to expand at a CAGR of 5.76%, reaching USD 819.46 million by 2030. Hospitals, surgical centers, and device manufacturers are aligning to deliver improved outcomes and substantial operational efficiencies within glaucoma care paradigms.

Scope & Segmentation

This market research analyzes a comprehensive range of segments and technologies shaping the global landscape for minimally invasive glaucoma surgery devices. Segmentation includes:

• Device Types: Ablation tools, catheters, lumen-based shunts (fixed-lumen, flow-controlled), scaffold/expanders, and stents.
• Surgical Sites: Ciliary body, Schlemm's canal, subconjunctival space, suprachoroidal space, trabecular meshwork.
• Indications: Angle-closure glaucoma, congenital glaucoma, primary open angle glaucoma, secondary glaucoma.
• Surgical Approaches: Ab externo, ab interno.
• Procedure Types: Combined with cataract surgery, standalone procedures.
• Implant Materials: Metals (nitinol, titanium) and polymers (gelatin, polyethersulfone, polyimide, silicone).
• Device Classes: Implantable and non-implantable devices.
• End Users: Ambulatory surgery centers, ophthalmic clinics, specialty eye hospitals.
• Distribution Channels: Offline and online platforms.
• Geographic Regions: Americas (United States, Canada, Mexico, Brazil, Argentina, Chile, Colombia, Peru); Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland, United Arab Emirates, Saudi Arabia, Qatar, Turkey, Israel, South Africa, Nigeria, Egypt, Kenya); Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan).
• Companies Profiled: Alcon Vision LLC, Johnson & Johnson Services, Inc., AbbVie Inc., Bausch + Lomb Corp., BVI Medical, Inc., Corza Ophthalmology Products, Inc., Nova Eye Medical Limited, Glaukos Corporation, Chengdu Kanghong Pharmaceutical Group Co., Ltd., Iridex Corporation, iSTAR Medical, Lumenis Be Ltd., New World Medical, Inc., Oertli Instrumente AG, Santen Pharmaceutical Co., Ltd., Sight Sciences, Inc., Rheon Medical SA, Ziemer Ophthalmic Systems AG, Lumibird Medical, Haag-Streit Group by Metall Zug AG, Lantrek, Inc., LIQID Medical (Pty) Ltd., Avisi Technologies, Inc.

Key Takeaways for Senior Decision-Makers

• MIGS devices are increasingly integrated earlier in the glaucoma treatment pathway, supporting improved patient quality of life and streamlined surgical workflows.
• Flexible implant platforms and modular systems now dominate device design, emphasizing intraoperative adaptability and combined procedure compatibility.
• Regulatory and payer landscapes are progressively recognizing patient outcomes and avoided interventions, driving demand for robust clinical and economic evidence.
• Digital diagnostics and AI-assisted tools are influencing candidate selection and post-operative management, further differentiating implant performance across patient populations.
• Manufacturing innovation and material advances are lowering barriers for new market entrants while compelling established providers to refine value propositions.
• Successful commercialization increasingly depends on region-specific reimbursement strategies, clinical data generation, and education focused on both cataract and glaucoma surgeons.

Tariff Impact: United States 2025 Tariffs

The introduction and adjustment of US tariffs in 2025 has compelled device manufacturers to reconsider sourcing, supplier diversification, and cost engineering. Responses include shifting toward domestic or nearshore suppliers, material substitution where viable, and increased attention to operational continuity and procurement agility. Health systems must weigh the benefits of established offerings against possible acquisition cost changes, while payers scrutinize the long-term value versus upfront pricing. The tariff environment has elevated the importance of supply chain resilience and scenario planning in strategic and commercial decision-making.

Methodology & Data Sources

This report integrates primary interviews with clinical leaders, procurement managers, and device manufacturers, combined with secondary analysis of peer-reviewed literature, regulatory filings, and policy documentation. Triangulation of these data sources ensures analytical rigor, practical validation, and up-to-date perspectives on market drivers and barriers.

Why This Report Matters

• Enables informed capital allocation and R&D direction by segmenting the market across device, indication, and regional dimensions.
• Supports executive and operational strategy with insights into regulatory, manufacturing, and reimbursement dynamics affected by recent tariff shifts.
• Empowers stakeholders to benchmark against leading innovators and to identify practical levers for accelerating adoption and risk mitigation.

Conclusion

The minimally invasive glaucoma surgery devices market is defined by clinical need, innovation in device design, and policy shifts that reward evidence-backed results. Stakeholders equipped with adaptable, data-driven strategies will be positioned to scale adoption and deliver value across diverse healthcare environments.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.